Emicizumab

(Hemlibra®)

Emicizumab

Drug updated on 11/13/2023

Dosage FormInjection (subcutaneous: 30 mg/mL, 60 mg/0.4 mL, 105 mg/0.7 mL, 150 mg/mL)
Drug ClassMultiple
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.